Search Results - "Forges, H."

Performance of four dual-energy CT platforms for abdominal imaging: a task-based image quality assessment based on phantom data by Greffier, J., Si-Mohamed, S., Dabli, D., de Forges, H., Hamard, A., Douek, P., Beregi, J. P., Frandon, J.

“…Objectives To compare the spectral performance of dual-energy CT (DECT) platforms using task-based image quality assessment based on phantom data. Materials…”
Get full text

MRI‐based score to predict surgical difficulty in patients with rectal cancer by Escal, L., Nougaret, S., Guiu, B., Bertrand, M. M., de Forges, H., Tetreau, R., Thézenas, S., Rouanet, P.

“…Background Rectal cancer surgery is technically challenging and depends on many factors. This study evaluated the ability of clinical and anatomical factors to…”
Get full text

Early MRI predictors of disease‐free survival in locally advanced rectal cancer from the GRECCAR 4 trial by Nougaret, S., Castan, F., Forges, H., Vargas, H. A., Gallix, B., Gourgou, S., Rouanet, P., Rullier, E., Lelong, B., Maingon, P., Tuech, J.‐J., Pezet, D., Rivoire, M., Meunier, B., Loriau, J., Valverde, A., Fabre, J.‐M., Prudhomme, M., Cotte, E., Portier, G., Quero, L., Gallix, B., Lemanski, C., Ychou, M., Bibeau, F.

“…Background Tailored neoadjuvant treatment of locally advanced rectal cancer (LARC) may improve outcomes. The aim of this study was to determine early MRI…”
Get full text

Impact of ultra-low dose CT acquisition on semi-automated RECIST tool in the evaluation of malignant focal liver lesions by Hamard, A., Frandon, J., Larbi, A., Goupil, J., De Forges, H., Beregi, J.-P., Greffier, J.

“…•Dosimetric values are significantly reduced by more than 50% with ultra-low dose CT protocol compared to standard dose CT protocol.•Semi-automated RECIST tool…”
Get full text

Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients by Samalin, E., Mazard, T., Assenat, E., Rouyer, M., De la Fouchardière, C., Guimbaud, R., Smith, D., Portales, F., Ychou, M., Fiess, C., de Forges, H., Lopez-Crapez, E., Thézenas, S.

Get full text

Prospective medical analysis of radiation therapist image repositioning during image-guided radiotherapy by Lauche, O., Castan, F., de Forges, H., Guillaumon, C., Gourgou, S., Fenoglietto, P., Aillères, N., Azria, D., Riou, O.

“…Radiation oncologists are responsible for deciding which day-to-day variations are acceptable or not in the treatment setup. However, properly qualified and…”
Get full text

SUN-LB280: Double Blind Multicenter Phase III Gortec Trial Evaluating the Efficacy of Oral Immune Modulating Formulae Therapy During Adjuvant Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) by Senesse, P.F, Graff-Cailleaud, P, Sire, C, Gallocher, O, Lavau-Denes, S, Garcia-Ramirez, M, Alfonsi, M, Cupissol, D, Kaminsky, M.-C, Fiore, S, Flori, N, de Forges, H, Garrel, R, Janiszewski, C, Thézénas, S, Boisselier, P

Get full text

98. Perioperative outcomes of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal carcinomatosis: PRODIGE 7 randomized trial by Quénet, F, Elias, D, Roca, L, Goéré, D, Ghouti, L, Pocard, M, Facy, O, Arvieux, C, Lorimier, G, Pezet, D, Marchal, F, Loi, V, Meeus, P, De Forges, H, Stanbury, T, Paineau, J, Glehen, O

Get full text

Two-stage hepatectomy for colorectal metastases: A good histo-pathologic response to intensified preoperative chemotherapy is associated with second-stage completion and longer survival by Pissas, M.-H, Bibeau, F, Gil, H, Roca, L, Lemoyne-de-Forges, H, Samalin, E, Carrere, S, Rouanet, P, Saint Aubert, B, Ychou, M, Quenet, F

Get full text

Valeur pronostique du relargage précoce de thyroglobuline au cours de l’irathérapie sous rh-TSH by Gall, E, Eberle, M.C., Dr, Deshayes, E., Dr, Raingeard, I., Dr, Lemoyne-De-Forges, H, Bringer, J., Pr

“…Objectifs Déterminer si la thyroglobuline (Tg) à j3, j6 et le ratio Tgj6/j3 au cours de l’irathérapie sous rh-TSH étaient prédictifs de rémission, et…”
Get full text

Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results: Qual Life Res by Bascoul-Mollevi, C., Barbieri, Antoine, Bourgier, C., Conroy, T., Chauffert, B., Hebbar, M., Jacot, W., Juzyna, B., de Forges, H., Gourgou, S., Bonnetain, F., Touraine, C., Anota, A.

“…PURPOSE: Health-related quality of life (HRQoL) is assessed by self-administered questionnaires throughout the care process. Classically, two longitudinal…”
Get full text

P-099Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients by Samalin, E, Mazard, T, Assenat, E, Rouyer, M, De la Fouchardière, C, Guimbaud, R, Smith, D, Portales, F, Ychou, M, Fiess, C, de Forges, H, Lopez-Crapez, E, Thézenas, S

Get full text

A UNICANCER phase III trial of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis. PRODIGE 7 by Quenet, F., Elias, D., Roca, L., Goéré, D., Ghouti, L., Pocard, M., Facy, O., Arvieux, C., Lorimier, G., Pezet, D., Marchal, F., Loi, V., Meeus, P., De Forges, H., Stanbury, T., Paineau, J., Glehen, O.

Get full text

Ambulatory mastectomy for cancer: Feasible and safe in consenting educated patients in a care network by Mourregot, A., Leclerc, G., Ducreux, L., Gutowski, M., Delmond, L., Colombo, P.-E., Carrere, S., Zoric, L., de Forges, H., Neron, M., Carrier, G., Rouanet, P.

“…Global policy encourages shorter periods of hospitalization in order to minimizing costs. In oncology, one-day surgery for breast cancer is well admitted for…”
Get full text

Étude multicentrique en double insu de phase III réalisée avec le Gortec et évaluant l’efficacité d’une solution orale immunomodulatrice dans les cancers épidermoïdes de la tête et du cou by Senesse, P.F., Graff-Cailleaud, P., Sire, C., Gallocher, O., Lavau-Denes, S., Garcia-Ramirez, M., Alfonsi, M., Cupissol, D., Kaminsky, M., Fiore, S., Flori, N., De Forges, H., Garrel, R., Janiszewski, C., Thézénas, S., Boisselier, P.

“…Un essai prospectif de phase 2 objectivait qu’une pharmaconutrition par voie orale en cours de chimioradiothérapie (CRT) des cancers de la tête et du cou,…”
Get full text